Search - tctmd.com

Displaying 461 - 480 of 514

Sort: Relevancy | Date

News Daily News

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Yael L. Maxwell

February 15, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

News Daily News

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

Jason Kahn

January 08, 2012

News Conference News

Adenosine-Free Pressure Measurement Found Equivalent to FFR

L.A. McKeown

December 01, 2011

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Industry News

Boston Scientific Receives FDA Approval for PROMUS Element™ Plus Platinum Chromium Stent System

November 21, 2011

News Conference News

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

November 20, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Industry News

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

November 10, 2011

News Industry News

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

November 09, 2011

News Industry News

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

November 08, 2011

News Industry News

Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System

November 07, 2011

News Conference News

DES and Stent Thrombosis Revisited

November 07, 2011

News Conference News

Evidence of Late Catch-up After DES ‘Unequivocal’

November 06, 2011

News Industry News

Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011

November 04, 2011

News Daily News

DES Associated with Less Downstream Lesion Development than BMS

L.A. McKeown

November 04, 2011

News Industry News

Micell Technologies Announces Presentation of Clinical Data at TCT 2011

November 02, 2011

News Industry News

Elixir Medical Corporation Announces Successful Completion of First-In-Man Study Enrollment for Fully Bioresorbable Drug Eluting Coronary Scaffold System

November 02, 2011

News Daily News

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

October 31, 2011

News Industry News

IVUS Cohort Recruitment Complete in Landmark Tryton IDE Study

October 26, 2011

Advertisement

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

Adenosine-Free Pressure Measurement Found Equivalent to FFR

Some New-Generation Stents Prone to Longitudinal Distortion

Boston Scientific Receives FDA Approval for PROMUS Element™ Plus Platinum Chromium Stent System

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System

DES and Stent Thrombosis Revisited

Evidence of Late Catch-up After DES ‘Unequivocal’

Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011

DES Associated with Less Downstream Lesion Development than BMS

Micell Technologies Announces Presentation of Clinical Data at TCT 2011

Elixir Medical Corporation Announces Successful Completion of First-In-Man Study Enrollment for Fully Bioresorbable Drug Eluting Coronary Scaffold System

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

IVUS Cohort Recruitment Complete in Landmark Tryton IDE Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content